Trial Profile
A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 21 Feb 2011 New trial record